NEWTON, Mass., July 15, 2026
Acumen Pharmaceuticals presented new preclinical and clinical research at the Alzheimer’s Association International Conference (AAIC) 2026 highlighting progress in its Enhanced Brain Delivery™ (EBD™) platform and new insights from patients enrolled in the Phase 2 ALTITUDE-AD trial. The company reported that its bispecific antibody candidate ACU401 achieved substantially improved brain penetration in non-human primates while maintaining a favorable safety profile, supporting the advancement of next-generation Alzheimer’s therapies.
Enhanced Brain Delivery Platform Demonstrates Superior Brain Penetration
Developed in collaboration with JCR Pharmaceuticals, Acumen’s EBD platform combines antibodies targeting soluble amyloid beta oligomers (AβOs) with transferrin receptor (TfR)-mediated brain delivery technology. Preclinical studies showed that EBD-enabled antibodies achieved significantly higher brain exposure than native anti-AβO antibodies while preserving target selectivity. In cynomolgus monkeys, lead candidate ACU401 demonstrated up to 40-fold greater exposure in the frontal cortex 24 hours after dosing, along with increased distribution in deeper brain regions, including the hippocampus and putamen. Researchers also reported no hematological safety findings suggestive of anemia, supporting the platform’s potential for continued development.
Patient Experience Data Highlight Early Alzheimer’s Disease Burden
Acumen also presented findings from interviews conducted with 38 participants and their study partners enrolled in the Phase 2 ALTITUDE-AD clinical trial. Participants described persistent challenges with memory, communication, and completing everyday tasks, alongside emotional effects such as frustration, anxiety, reduced confidence, and social withdrawal. Many also reported masking symptoms or selectively disclosing cognitive difficulties, emphasizing the importance of incorporating patient-reported experiences into Alzheimer’s clinical research and treatment evaluation.
Advertisement
Acumen Advances Alzheimer’s Pipeline Across Multiple Technologies
The company continues to advance sabirnetug (ACU193), its investigational monoclonal antibody targeting toxic soluble amyloid beta oligomers, through the ongoing Phase 2 ALTITUDE-AD trial evaluating patients with early Alzheimer’s disease. Topline results are expected in late 2026. Alongside sabirnetug, Acumen is expanding its Alzheimer’s pipeline through its collaboration with JCR Pharmaceuticals to develop Enhanced Brain Delivery-enabled therapies designed to improve drug delivery across the blood-brain barrier while potentially enabling lower therapeutic doses and more convenient administration for patients.
Source: Acumen Pharmaceuticals press release
